Clinical Trial – Effect of Secukinumab in PsA – Psoriasis Arthritis

The study is designed to investigate, in detail, the clinical and molecular effects of secukinumab(Cosentyx) in the treatment of Psoriasis Arthritis.

The investigators will also make use of the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Exploration of the Dynamic Interaction Between IL-17, IL-17 Inhibition With (Secukinumab) and Neutrophils in Psoriatic Arthritis in Vitro and ex Vivo With Exploratory Study on the Potential Role of Vitamin D
Study Start Date : October 2016
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : August 2018
Contacts
Contact: Laurence S Loubiere, PhD loubiere@liverpool.ac.uk
ClinicalTrials.gov Identifier: NCT02854163

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.